Bristol Myers Squibb (CELG-RI) Total Debt (2009 - 2026)
Bristol Myers Squibb (CELG-RI) posted quarterly Total Debt of $43.9 billion for Q2 2026, down 18.21% year-over-year from $53.7 billion in Q2 2025, and down 5.51% quarter-over-quarter from $46.4 billion in Q1 2026.
Bristol Myers Squibb (CELG-RI) Total Debt (2009 - 2026) Analysis & Trends
Bristol Myers Squibb (CELG-RI) has reported Total Debt for 18 consecutive years, with $43.9 billion the latest figure, recorded in Q2 2026.
- In Q2 2026, Total Debt fell 18.21% year-over-year to $43.9 billion; the TTM figure through Jun 2026 stood at $43.9 billion (down 18.21% YoY), while the FY2025 annual figure was $47.1 billion, down 8.53% from the prior year.
- Total Debt slipped to $43.9 billion in Q2 2026 per CELG-RI's latest filing, from $46.4 billion in the prior quarter.
- Across five years, Total Debt topped out at $58.6 billion in Q1 2024 and bottomed at $40.1 billion in Q1 2023.
- Historically, Total Debt has averaged $47.9 billion across 5 years, with a median of $46.9 billion in 2022.
- Annual changes were most pronounced in 2023 — Total Debt retreated 23.31% — and 2024, when it surged 46.07%.
- Bristol Myers Squibb's Total Debt stood at $43.2 billion in 2022, then retreated by 1.32% to $42.6 billion in 2023, then rose by 20.71% to $51.5 billion in 2024, then slipped by 8.53% to $47.1 billion in 2025, then decreased by 6.8% to $43.9 billion in 2026.
- Business Quant data shows CELG-RI's Total Debt at $43.9 billion in Q2 2026, $46.4 billion in Q1 2026, and $47.1 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 653.90 Bn | 633.14 Bn | 17.26 Bn | 49.04 Bn |
| 2 | AbbVie | 470.19 Bn | 463.62 Bn | 12.70 Bn | 70.82 Bn |
| 3 | Merck | 377.19 Bn | 370.05 Bn | 12.21 Bn | 53.91 Bn |
| 4 | Novartis Ag | 303.28 Bn | 295.59 Bn | 11.24 Bn | 9.59 Bn |
| 5 | Astrazeneca | 257.67 Bn | 252.77 Bn | 12.86 Bn | 29.49 Bn |
| 6 | Amgen | 236.95 Bn | 222.96 Bn | 7.24 Bn | 62.75 Bn |
| 7 | Gilead Sciences | 182.20 Bn | 179.02 Bn | 6.22 Bn | 28.66 Bn |
| 8 | Pfizer | 159.32 Bn | 147.62 Bn | 10.94 Bn | 63.19 Bn |
| 9 | Gsk | 106.10 Bn | 101.93 Bn | 8.24 Bn | -25.96 Bn |
| 10 | Bristol Myers Squibb | 224.21 Mn | -10.84 Bn | 9.25 Bn | 43.89 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 43.89 Bn |
| Mar 31, 2026 | 46.45 Bn |
| Dec 31, 2025 | 45.11 Bn |
| Sep 30, 2025 | 48.98 Bn |
| Jun 30, 2025 | 53.66 Bn |
| Mar 31, 2025 | 49.71 Bn |
| Dec 31, 2024 | 51.48 Bn |
| Sep 30, 2024 | 49.75 Bn |
| Jun 30, 2024 | 55.48 Bn |
| Mar 31, 2024 | 55.68 Bn |
| Dec 31, 2023 | 42.65 Bn |
| Sep 30, 2023 | 37.60 Bn |
| Jun 30, 2023 | 37.68 Bn |
| Mar 31, 2023 | 37.83 Bn |
| Dec 31, 2022 | 43.22 Bn |
| Sep 30, 2022 | 41.00 Bn |
| Jun 30, 2022 | 42.06 Bn |
| Mar 31, 2022 | 52.27 Bn |
| Dec 31, 2021 | 44.55 Bn |
| Sep 30, 2021 | 49.51 Bn |